Fundraising Fox

Neurana Pharmaceuticals

San Diego, US · Founded 2013 · Delaware corporation · 3 known investors

Developing a novel treatment for acute muscle spasms.

Biotech

Founders & leadership

KD
Kathleen D. ScottChief Financial Officer, Secretary and Treasurer
JC
Judy CaronChief Operating Officer
DF
David F. HaleChairman of the Board of Directors, Acting President and CEO
BD
Brian DorseyNamed on SEC filing
DB
Daniel BeckerNamed on SEC filing
JR
Joshua RichardsonNamed on SEC filing

Board

AZ
Alex ZissonBoard directorManaging Director at H.I.G. HealthBridge Partners
DKDavid Kabakoff
David KabakoffBoard directorExecutive Partner, Private Equity at Sofinnova Ventures

Investors · 3

Sofinnova VenturesMenlo Park · $100K – $15M
H.I.G. HealthBridge PartnersreportedMiami · $5M – $40Mvia Alex Zisson · board
Longitude CapitalreportedMenlo Park · $10M – $30M

Reported raises · per SEC filings

Form D private placements

$45.7M disclosed across 2 rounds · 2013–2018

▶$41.9MraisedFeb 2020 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joshua RichardsonDirector
  • David KabakoffDirector
  • Craig ThompsonDirector, Executive Officer
  • Brian DorseyDirector
  • David F. HaleDirector
  • Randall Kaye, M.D.Executive Officer
  • Kathleen D. ScottExecutive Officer
  • Alex ZissonDirector
Offering amount
$64.9M
Amount sold
$41.9M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedMay 2018 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathleen D. ScottExecutive Officer
  • Judy CaronExecutive Officer
  • David F. HaleDirector, Executive Officer
  • Brian DorseyDirector
  • Daniel BeckerDirector
  • Alex ZissonDirector
  • David KabakoffDirector
  • Joshua RichardsonDirector
Offering amount
$3.8M
Amount sold
$3.8M
First sale
Dec 2013
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

San Diego California based Neurana Pharmaceuticals is raising $64,888,250.00 in New Equity Investment. - intelligence360intelligence360.news · Mar 2020Neurana’s non-opioid back pain drug passes midstage human testingsandiegouniontribune.com · Sep 2019Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back - BioSpacebiospace.com · Sep 2019Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing - BioSpacebiospace.com · May 2018Neurana Pharmaceuticals 5/8/2018 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

What does Neurana Pharmaceuticals do?
Developing a novel treatment for acute muscle spasms.
Who are Neurana Pharmaceuticals's investors?
Neurana Pharmaceuticals's investors include Sofinnova Ventures, H.I.G. HealthBridge Partners, Longitude Capital.
How much funding has Neurana Pharmaceuticals raised?
Neurana Pharmaceuticals has disclosed $45.7M raised across 2 rounds.
Where is Neurana Pharmaceuticals headquartered?
Neurana Pharmaceuticals is headquartered in San Diego, US.